Clovis Oncology Gross Profit

Clovis Oncology (CLVS) currently reports a gross profit of $100M as of September 2022. That compares with $120M in the prior-year period — down 16.6% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Clovis Oncology's gross profit history and peer comparisons.

Clovis Oncology's gross profit decreased from $120M to $100M — a 16.6% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clovis Oncology's gross profit of $100M is lower than the Healthcare sector average of $67B. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Clovis Oncology reported $100M in gross profit as of September 2022. That compares with $120M in the prior-year period — down 16.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Clovis Oncology, and consider following CLVS for alerts when major investors trade the stock.